C-terminal amidation is a PTM that involves the addition of an amid group to the C-terminus of a peptide or protein. Currently there is no direct evidence to suggest that C-terminal amidation of ...

The team concentrated on the proteasome, which functions as a sort of recycling bin for the cell. Through the operations of ...

Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...